Literature DB >> 17912702

Dimethylsphingosine and FTY720 inhibit the SK1 form but activate the SK2 form of sphingosine kinase from rat heart.

Donald A Vessey1, Michael Kelley, Jianqing Zhang, Luyi Li, Rong Tao, Joel S Karliner.   

Abstract

Fractionation of cytosolic sphingosine kinase (SKase) activity by gel filtration chromatography gave rise to a 96-kDa peak that contained only the SK2 form of SKase (by Western analysis) and a broad ca. 46 kDa peak that contained only SK1 forms. SK2 appeared to have a bound accessory protein. When tested with the classic SKase inhibitor dimethylsphingosine (DMS), SK1 was extensively inhibited; however, SK2 was not inhibited but unexpectedly was activated. Activation of SK2 was the result of DMS enhancing the affinity of the enzyme for sphingosine, and, at low concentrations of ATP and sphingosine, activated by more than 100%. Activation of SK2 could be demonstrated in the cytosolic fraction indicating it was unrelated to the purification step. The immunomodulator FTY720 also activated SK2 (although to a lesser extent), but was a potent inhibitor of SK1. SK2 from rat liver and spleen was also not inhibited by DMS. L-Sphingosine and to a lesser extent dihydrosphingosine and phytosphingosine were effective inhibitors of both forms. (c) 2007 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17912702     DOI: 10.1002/jbt.20193

Source DB:  PubMed          Journal:  J Biochem Mol Toxicol        ISSN: 1095-6670            Impact factor:   3.642


  41 in total

Review 1.  Sphingosine kinase regulation and cardioprotection.

Authors:  Joel S Karliner
Journal:  Cardiovasc Res       Date:  2008-11-18       Impact factor: 10.787

2.  Essential Role of Sphingosine Kinase 2 in the Regulation of Cargo Contents in the Exosomes from K562 Cells.

Authors:  Nesma Nabil Ibrahim Mohamed; Taro Okada; Taketoshi Kajimoto; Shun-Ichi Nakamura
Journal:  Kobe J Med Sci       Date:  2018-05-25

3.  Sphingosine kinase 2 mediates cerebral preconditioning and protects the mouse brain against ischemic injury.

Authors:  Lai Ming Yung; Ying Wei; Tao Qin; Yumei Wang; Charles D Smith; Christian Waeber
Journal:  Stroke       Date:  2011-10-06       Impact factor: 7.914

Review 4.  Sphingosine kinase and sphingosine 1-phosphate in the heart: a decade of progress.

Authors:  Joel S Karliner
Journal:  Biochim Biophys Acta       Date:  2012-06-23

5.  Sphingolipid-based drugs selectively kill cancer cells by down-regulating nutrient transporter proteins.

Authors:  Kimberly Romero Rosales; Gurpreet Singh; Kevin Wu; Jie Chen; Matthew R Janes; Michael B Lilly; Eigen R Peralta; Leah J Siskind; Michael J Bennett; David A Fruman; Aimee L Edinger
Journal:  Biochem J       Date:  2011-10-15       Impact factor: 3.857

Review 6.  Therapeutic potential of targeting sphingosine kinase 1 in prostate cancer.

Authors:  Dmitri Pchejetski; Torsten Böhler; Justin Stebbing; Jonathan Waxman
Journal:  Nat Rev Urol       Date:  2011-09-13       Impact factor: 14.432

7.  Sphingosine protects aging hearts from ischemia/reperfusion injury: Superiority to sphingosine 1-phosphate and ischemic pre- and post-conditioning.

Authors:  Donald A Vessey; Michael Kelley; Luyi Li; Yong Huang
Journal:  Oxid Med Cell Longev       Date:  2009 Jul-Aug       Impact factor: 6.543

8.  FTY720 and (S)-FTY720 vinylphosphonate inhibit sphingosine kinase 1 and promote its proteasomal degradation in human pulmonary artery smooth muscle, breast cancer and androgen-independent prostate cancer cells.

Authors:  Francesca Tonelli; Keng Gat Lim; Carolyn Loveridge; Jaclyn Long; Stuart M Pitson; Gabor Tigyi; Robert Bittman; Susan Pyne; Nigel J Pyne
Journal:  Cell Signal       Date:  2010-06-04       Impact factor: 4.315

Review 9.  Sphingolipids: regulators of crosstalk between apoptosis and autophagy.

Authors:  Megan M Young; Mark Kester; Hong-Gang Wang
Journal:  J Lipid Res       Date:  2012-11-13       Impact factor: 5.922

10.  Sphingolipids in cardiovascular and cerebrovascular systems: Pathological implications and potential therapeutic targets.

Authors:  Masahito Kawabori; Rachid Kacimi; Joel S Karliner; Midori A Yenari
Journal:  World J Cardiol       Date:  2013-04-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.